Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 4/2015

01-12-2015 | NON-THEMATIC REVIEW

Breast carcinoma metastasis suppressor gene 1 (BRMS1): update on its role as the suppressor of cancer metastases

Authors: Magdalena Anna Kodura, Serhiy Souchelnytskyi

Published in: Cancer and Metastasis Reviews | Issue 4/2015

Login to get access

Abstract

BRMS1 was discovered over a decade ago as a potential tumor suppressor gene. In this review, we summarize the recent findings about the structure of BRMS1, mechanisms of its action and a role of BRMS1 in the cancer progression. As a suppressor of metastasis, BRMS1 has demonstrated a variety of ways to act on the cell functions, such as cell migration, invasiveness, angiogenesis, cell survival, cytoskeleton rearrangements, cell adhesion, and immune recognition. This variety of effects is a likely reason behind the robustness of anti-metastatic influence of BRMS1. Intracellular signaling mechanisms employed by BRMS1 include regulation of transcription, EGF/HER2 signaling, and expression of NF-kB, fascin, osteopontin, and IL-6. Recently reported clinical studies confirm that BRMS1 can indeed be used as a prognostic marker. Approaches to employ BRMS1 in a development of anti-cancer treatment have also been made. The studies reviewed here with respect to BRMS1 structure, cellular effects, intracellular signaling, and clinical value consolidate the importance of BRMS1 in the development of metastasis.
Literature
1.
Seraj, M. J., Samant, R. S., Verderame, M. F., & Welch, D. R. (2000). Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMS1, encoded at chromosome 11q13. Cancer Research, 60(11), 2764–2769.PubMed
2.
Samant, R. S., Seraj, M. J., Saunders, M. M., Sakamaki, T. S., Shevde, L. A., Harms, J. F., et al. (2000). Analysis of mechanisms underlying BRMS1 suppression of metastasis. Clinical and Experimental Metastasis, 18(8), 683–693.PubMedCrossRef
3.
Song, S., & Yuan, Y. (2013). The Drosophila ortholog of breast cancer metastasis suppresion gene, dBRMS1, is critical for developmental timing through regulating ecdysone signaling. Developmental Biology, 380(2), 344–350.PubMedCrossRef
4.
Hurst, D. R., Xie, Y., Edmonds, M. D., & Welch, D. R. (2009). Multiple forms of BRMS1 are differentially expressed in the MCF10 isogenic breast cancer progression model. Clinical and Experimental Metastasis, 26(2), 89–96.PubMedCentralPubMedCrossRef
5.
Nikolaev, A. Y., Papanikolaou, N. A., Li, M., Qin, J., & Gu, W. (2004). Identification of a Nobel BRMS1-homologue protein p40 as a component of a mSin3A/p33(ING1b)/HDAC1 deacetylase complex. Biochemical and Biophysical Research Community, 323(4), 1216–1222.CrossRef
6.
Yang, J., Zhang, B., Lin, Y., Yang, Y., Liu, X., & Lu, F. (2008). Breast cancer metastasis suppressor 1 inhibits SDF-1alpha-induced migration of non-small cell lung cancer by decreasing CXCR4 expression. Cancer Letters, 269(1), 46–56.PubMedCrossRef
7.
Zhang, S., Lin, Q. D., & DI, W. (2006). Suppression of human ovarian carcinoma metastasis by the metastasis-suppressor gene, BRMS1. International Journal of Gynecological Cancer, 16(2), 522–531.PubMedCrossRef
8.
Slipicevic, A., Holm, R., Emilsen, E., Ree Rosnes, A. K., Welch, D. R., Mælandsmo, G. M., et al. (2012). Cytoplasmic BRMS1 expression in malignant melanoma is associated with increased disease-free survival. BMC Cancer. doi:10.​1186/​1471-2407-12-73.PubMedCentralPubMed
9.
Zhang, Y., Guan, J., Sun, Y., Chai, J., Zou, T., Gong, W., et al. (2014). Effect of BRMS1 on tumorigenicity and metastasis of human rectal cancer. Cell Biochemistry and Biophysics, 70(1), 505–509.PubMedCrossRef
10.
Spínola-Amilibia, M., Rivera, J., Ortiz-Lombardía, M., Romero, A., Neira, J. L., & Bravo, J. (2011). The structure of BRMS1 nuclear export signal and SNX6 interacting region reveals a hexamer formed by antiparallel coiled coils. Journal of Molecular Biology, 411(5), 1114–1127.PubMedCrossRef
11.
Hurst, D. R., Xie, Y., Vaidya, K. S., Mehta, A., Moore, B. P., Accavitti-Loper, M. A., et al. (2008). Alterations of BRMS1-ARID4A interaction modify gene expression but still suppress metastasis in human breast cancer cells. Journal of Biological Chemistry, 283(12), 7438–7444.PubMedCentralPubMedCrossRef
12.
Wu, J., Wang, Y., Qiao, X., Saiyin, H., Zhao, S., Qiao, S., et al. (2013). Cloning and characterization of a novel human BRMS1 transcript variant in hepatocellular carcinoma cells. Cancer Letters, 337(2), 266–275.PubMedCrossRef
13.
Zhang, Y., Ye, L., Tan, Y., Sun, P., Ji, K., & Jiang, W. G. (2014). Expression of breast cancer metastasis suppressor-1, BRMS-1, in human breast cancer and the biological impact of BRMS-1 on the migration of breast cancer cells. Journal Anticancer Research, 34(3), 1417–1426.PubMed
14.
15.
Phadke, P. A., Vaidya, K. S., Nash, K. T., Hurst, D. R., & Welch, D. R. (2008). BRMS1 suppresses breast cancer experimental metastasis to multiple organs by inhibiting several steps of the metastatic process. American Journal of Pathology, 172(3), 809–817.PubMedCentralPubMedCrossRef
16.
Samant, R. S., Debies, M. T., Hurst, D. R., Moore, B. P., Shevde, L. A., & Welch, D. R. (2006). Suppression of murine mammary carcinoma metastasis by the murine ortholog of breast cancer metastasis suppressor 1 (Brms1). Cancer Letters, 235(2), 260–265.PubMedCrossRef
17.
Li, J., & Li, G. (2010). Cell cycle regulator ING4 is a suppressor of melanoma angiogenesis that is regulated by the metastasis suppressor BRMS1. Cancer Research, 70(24), 10445–10453.PubMedCrossRef
18.
Hedley, B. D., Vaidya, K. S., Phadke, P., MacKenzie, L., Dales, D. W., & Postenka, C. O. (2008). BRMS1 suppresses breast cancer metastasis in multiple experimental models of metastasis by reducing solitary cell survival and inhibiting growth initiation. Clinical and Experimental Metastasis, 25(7), 727–740.PubMedCrossRef
19.
Wu, Y., Jiang, W., Wang, Y., Wu, J., Saiyin, H., Qiao, X., et al. (2012). Breast cancer metastasis suppressor 1 regulates hepatocellular carcinoma cell apoptosis via suppressing osteopontin expression. PLoS One. doi:10.​1371/​journal.​pone.​0042976.
20.
21.
Liu, Y., Smith, P. W., & Jones, D. R. (2006). Breast cancer metastasis suppressor 1 functions as a corepressor by enhancing histone deacetylase 1-mediated deacetylation of RelA/p65 and promoting apoptosis. Molecular and Cellular Biology, 26(23), 8683–8696.PubMedCentralPubMedCrossRef
22.
Wu, Y., McEwen, G. D., Harihar, S., Baker, S. M., DeWald, D. B., & Zhou, A. (2010). BRMS1 expression alters the ultrastructural, biomechanical and biochemical properties of MDA-MB-435 human breast carcinoma cells: an AFM and Raman microspectroscopy study. Cancer Letters, 293(1), 82–91.PubMedCrossRef
23.
Khotskaya, Y. B., Beck, B. H., Hurst, D. R., Han, Z., Xia, W., Hung, M. C., et al. (2014). Expression of metastasis suppressor BRMS1 in breast cancer cells results in a marked delay in cellular adhesion to matrix. Molecular Carcinogenesis, 53(12), 1011–1026.PubMed
24.
Vaidya, K. S., Harihar, S., Phadke, P., Stafford, L. J., Hurst, D., Hicks, D. G., et al. (2008). Breast cancer metastasis suppressor-1 differentially modulates growth factor signaling. Journal of Biological Chemistry, 283(42), 28354–28360.PubMedCentralPubMedCrossRef
25.
Saunders, M. M., Seraj, M. J., Li, Z., Zhou, Z., Winter, C. R., Welch, D. R., et al. (2001). Breast cancer metastatic potential correlates with a breakdown in homospecific and heterospecific gap junctional intercellular communication. Cancer Research, 61(5), 1765–1767.PubMed
26.
Shevde, L. A., Samant, R. S., Goldberg, S. F., Sikaneta, T., Alessandrini, A., Donahue, H. J., et al. (2002). Suppression of human melanoma metastasis by the metastasis suppressor gene, BRMS1. Experimental Cell Research, 273(2), 229–239.PubMedCrossRef
27.
Meehan, W. J., & Welch, D. R. (2003). Breast cancer metastasis suppressor 1: update. Clinical and Experimental Metastasis, 20(1), 45–50.PubMedCrossRef
28.
Kapoor, P., Saunders, M. M., Li, Z., Zhou, Z., Sheaffer, N., & Kunze, E. L. (2004). Breast cancer metastatic potential: correlation with increased heterotypic gap junctional intercellular communication between breast cancer cells and osteoblastic cells. International Journal of Cancer, 111(5), 693–697.CrossRef
29.
Jiang, J., Xia, M., Feng, J. B., & Kong, B. H. (2007). Inhibitory effect of breast cancer metastasis suppressor l gene on metastasis of human ovarian cancer cell in vitro and in vivo. Zhonghua Fu Chan Ke Za Zhi, 42(6), 398–402.PubMed
30.
Hall, E. H., Liu, Y., Xiao, A., Shock, L., Brautigan, D. L., & Mayo, M. W. (2014). Inhibition of breast cancer metastasis suppressor 1 promotes a mesenchymal phenotype in lung epithelial cells that express oncogenic K-RasV12 and loss of p53. PLoS One. doi:10.​1371/​journal.​pone.​0095869.
31.
Liu, Y., Mayo, M. W., Xiao, A., Hall, E. H., Amin, E. B., & Kadota, K. (2015). Loss of BRMS1 promotes a mesenchymal phenotype through NF-κB-dependent regulation of twist 1. Molecular and Cellular Biology, 35(1), 303–317.PubMedCentralPubMedCrossRef
32.
Champine, P. J., Michaelson, J., Weimer, B. C., Welch, D. R., & DeWald, D. B. (2007). Microarray analysis reveals potential mechanisms of BRMS1-mediated metastasis suppression. Clinical and Experimental Metastasis, 24(7), 551–565.PubMedCentralPubMedCrossRef
33.
Hurst, D. R. (2012). Metastasis suppression by BRMS1 associated with SIN3 chromatin remodeling complexes. Cancer Metastasis Reviews, 31(3–4), 641–651.PubMedCrossRef
34.
Meehan, W. J., Samant, R. S., Hopper, J. E., Carrozza, M. J., Shevde, L. A., Workman, J. L., et al. (2004). Breast cancer metastasis suppressor 1 (BRMS1) forms complexes with retinoblastoma-binding protein 1 (RBP1) and the mSin3 histone deacetylase complex and represses transcription. Journal of Biological Chemistry, 279(2), 1562–1569.PubMedCrossRef
35.
Cui, R. X., Liu, N., He, Q. M., Li, W. F., Huang, B. J., Sun, Y., et al. (2012). Low BRMS1 expression promotes nasopharyngeal carcinoma metastasis in vitro and in vivo and is associated with poor patient survival. BMC Cancer. doi:10.​1186/​1471-2407-12-376.
36.
Chimonidou, M., Strati, A., Tzitzira, A., Sotiropoulou, G., Malamos, N., Georgoulias, V., et al. (2011). DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells. Clinical Chemistry, 57(8), 1169–1177.PubMedCrossRef
37.
Li, J., Cheng, Y., Tai, D., Martinka, M., Welch, D. R., & Li, G. (2011). Prognostic significance of BRMS1 expression in human melanoma and its role in tumor angiogenesis. Oncogene, 30(8), 896–906.PubMedCentralPubMedCrossRef
38.
Cicek, M., Fukuyama, R., Welch, D. R., Sizemore, N., & Casey, G. (2005). Breast cancer metastasis suppressor 1 inhibits gene expression by targeting nuclear factor-kappaB activity. Cancer Research, 65(9), 3586–3595.PubMedCrossRef
39.
Sheng, X. J., Zhou, D. M., Liu, Q., Lou, S. Y., Song, Q. Y., & Zhou, Y. Q. (2014). BRMS1 inhibits expression of NF-kappaB subunit p65, uPA and OPN in ovarian cancer cells. European Journal of Gynaecological Oncology, 35(3), 236–242.PubMed
40.
Hurst, D. R., Edmonds, M. D., Scott, G. K., Benz, C. C., Vaidya, K. S., & Welch, D. R. (2009). Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Research, 69(4), 1279–1283.PubMedCentralPubMedCrossRef
41.
Hicks, D., Yoder, B. J., Short, S., Tarr, S., Prescott, N., Crowe, J. P., et al. (2006). Loss of breast cancer metastasis suppressor 1 protein expression predicts reduced disease-free survival in some breast cancer patients. Clinical Cancer Research, 12(22), 6702–6708.PubMedCentralPubMedCrossRef
42.
43.
Rivera, J., Megías, D., & Bravo, J. (2010). Sorting nexin 6 interacts with breast cancer metastasis suppressor-1 and promotes transcriptional repression. Journal of Cellular Biochemistry, 111(6), 1464–1472.PubMedCrossRef
44.
Hedley, B. D., Welch, D. R., Allan, A. L., Al-Katib, W., Dales, D. W., Postenka, C. O., et al. (2008). Downregulation of osteopontin contributes to metastasis suppression by breast cancer metastasis suppressor 1. International Journal of Cancer, 123(3), 526–534.CrossRef
45.
Metge, B. J., Liu, S., Riker, A. I., Fodstad, O., Samant, R. S., & Shevde, L. A. (2010). Elevated osteopontin levels in metastatic melanoma correlate with epigenetic silencing of breast cancer metastasis suppressor 1. Oncology, 78(1), 75–86.PubMedCrossRef
46.
Samant, R. S., Clark, D. W., Fillmore, R. A., Cicek, M., Metge, B. J., Chandramouli, K. H., et al. (2007). Breast cancer metastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-kappaB activation. Molecular Cancer. doi:10.​1186/​1476-4598-6-6.PubMedCentralPubMed
47.
Rivera, J., Megias, D., & Bravo, J. (2007). Proteomics-based strategy to delineate the molecular mechanisms of the metastasis suppressor gene BRMS1. Journal of Proteome Research, 6(10), 4006–4018.PubMedCrossRef
48.
Zhang, Y., Chin-Quee, K., Riddle, R. C., Li, Z., Zhou, Z., & Donahue, H. J. (2013). BRMS1 sensitizes breast cancer cells to ATP-induced growth suppression. Bioresource Open Access, 2(2), 77–83.CrossRef
49.
Liu, Y., Mayo, M. W., Nagji, A. S., Hall, E. H., Shock, L. S., Xiao, A., et al. (2013). BRMS1 suppresses lung cancer metastasis through an E3 ligase function on his tone acetyltransferase p300. Cancer Research, 73(4), 1308–1317.PubMedCentralPubMedCrossRef
50.
Metge, B. J., Frost, A. R., King, J. A., Dyess, D. L., Welch, D. R., Samant, R. S., et al. (2008). Epigenetic silencing contributes to the loss of BRMS1 expression in breast cancer. Clinical and Experimental Metastasis, 25(7), 753–763.PubMedCentralPubMedCrossRef
51.
Szarc vel Szic, K., Op de Beeck, K., Ratman, D., Wouters, A., Beck, I. M., Declerck, K., et al. (2014). Pharmacological levels of Withaferin A (Withania somnifera) trigger clinically relevant anticancer effects specific to triple negative breast cancer cells. PLoS One. doi:10.​1371/​journal.​pone.​0087850.
52.
Zhang, Z., Yamashita, H., Toyama, T., Yamamoto, Y., Kawasoe, T., & Iwase, H. (2006). Reduced expression of the breast cancer metastasis suppressor 1 mRNA is correlated with poor progress in breast cancer. Clinical Cancer Research, 12(21), 6410–6414.PubMedCrossRef
53.
Stark, A. M., Tongers, K., & Maass, N. (2005). Reduced metastasis-suppressor gene mRNA expression in breast cancer metastases. Journal of Cancer Research and Clinical Oncology, 131(3), 191–198.PubMedCrossRef
54.
Yang, J., Shen, Y., Liu, B., & Tong, Y. (2011). Promoter methylation of BRMS1 correlates with smoking history and poor survival in non-small cell lung cancer patients. Lung Cancer, 74(2), 305–309.PubMedCrossRef
55.
Smith, J., Naseem, R., & Webb, M. (2009). Purification and characterisation of the breast cancer metastasis suppressor, BRMS1. Protein Expression and Purification, 67(2), 70–75.PubMedCrossRef
56.
Li, J., Zhang, Z., & Li, G. (2011). Patient outcome prediction using multiple biomarkers in human melanoma: a clinicopathological study of 118 cases. Experimental Therapeutics Medicine, 2(1), 131–135.
57.
Chimonidou, M., Kallergi, G., Georgoulias, V., Welch, D. R., & Lianidou, E. S. (2013). Breast cancer metastasis suppressor-1 promoter methylation in primary breast tumors and corresponding circulating tumor cells. Molecular Cancer Research, 11(10), 1248–1257.PubMedCrossRef
58.
Balgkouranidou, I., Chimonidou, M., Milaki, G., Tsarouxa, E. G., Kakolyris, S., Welch, D. R., et al. (2014). Breast cancer metastasis suppressor-1 promoter methylation in cell-free DNA provides prognostic information in non-small cell lung cancer. British Journal Cancer, 110(8), 2054–2062.CrossRef
59.
Nagji, A. S., Liu, Y., Stelow, E. B., Stukenborg, G. J., & Jones, D. R. (2010). BRMS1 transcriptional repression correlates with CpG island methylation and advanced pathological stage in non-small cell lung cancer. Journal of Pathology, 221(2), 229–237.PubMedCentralPubMedCrossRef
60.
Kelly, L. M., Buggy, Y., Hill, A., O’Donovan, N., Duggan, C., McDermott, E. W., et al. (2005). Expression of the breast cancer metastasis suppressor gene, BRMS1, in human breast carcinoma: lack of correlation with metastasis to axillary lymph nodes. Tumour Biology, 26(4), 213–216.PubMedCrossRef
61.
Cook, L. M., Cao, X., Dowell, A. E., Debies, M. T., Edmonds, M. D., Beck, B. H., et al. (2012). Ubiquitous Brms1 expression is critical for mammary carcinoma metastasis suppression via promotion of apoptosis. Clinical and Experimental Metastasis, 29(4), 315–325.PubMedCentralPubMedCrossRef
62.
63.
64.
Frolova, N., Edmonds, M. D., Bodenstine, T. M., Seitz, R., Johnson, M. R., Feng, R., et al. (2009). A shift from nuclear to cytoplasmic breast cancer metastasis suppressor 1 expression is associated with highly proliferative estrogen receptor-negative breast cancers. Tumour Biology, 30(3), 148–159.PubMedCentralPubMedCrossRef
65.
Hurst, D. R., Xie, Y., Thomas, J. W., Liu, J., Edmonds, M. D., Stewart, M. D., et al. (2013). The C-terminal putative nuclear localization sequence of breast cancer metastasis suppressor 1, BRMS1, is necessary for metastasis suppression. PLoS One. doi:10.​1371/​journal.​pone.​0055966.
66.
Gomez, H., Neciosup, S., Tosello, C., Mano, M., Bines, J., Ismael, G., et al. (2012). A randomized open-label, phase ii study of lapatinib-capecitabine or lapatinib-vinorelbine or lapatinib/gemcitabine in subjects with Her2/neu amplified metastatic breast cancer patients progression after taxanes treatment, 2012 ASCO Annual Meeting Proceedings, Abstract No: e11087, Study ID: GLICO-0801.
Metadata
Title
Breast carcinoma metastasis suppressor gene 1 (BRMS1): update on its role as the suppressor of cancer metastases
Authors
Magdalena Anna Kodura
Serhiy Souchelnytskyi
Publication date
01-12-2015
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 4/2015
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-015-9583-z

Other articles of this Issue 4/2015

Cancer and Metastasis Reviews 4/2015 Go to the issue

Non-Thematic Review

Retinoblastoma: might photodynamic therapy be an option?

NON-THEMATIC REVIEW

Tumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategies

CLINICAL

Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?

Non-Thematic Review

Contribution of very late antigen-4 (VLA-4) integrin to cancer progression and metastasis

NON-THEMATIC REVIEW

Neutrophils: important contributors to tumor progression and metastasis

CLINICAL

New advances in ovarian autotransplantation to restore fertility in cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits